Form 4: Immunome Director Sells Shares via 10b5-1 Plan

Immunome Inc. Director Isaac Barchas reported the sale of 383,200 common shares through pre-arranged trading plans.

Summary

• Director Isaac Barchas reported the sale of 383,200 shares of Immunome Inc. common stock.
• The sales occurred on December 22, 2025, pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2024.
• A total of 371,949 shares were sold at a weighted average price of $21.72, with prices ranging from $21.31 to $22.30.
• An additional 11,251 shares were sold at a weighted average price of $22.34, with prices ranging from $22.31 to $22.38.
• These shares were sold by Arsenal Bridge Venture II, LLC and Arsenal Bridge Venture II-B, LLC, entities over which Mr. Barchas holds voting and investment power.
• Following these transactions, the ABV Entities collectively own 2,031,181 shares of Immunome common stock.
• Mr. Barchas also transferred 29,469 shares to his ex-spouse pursuant to a domestic relations order, which are no longer reported as beneficially owned by him.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are pre-planned sales under a Rule 10b5-1 plan, which typically do not reflect new discretionary insider sentiment regarding the company's prospects. The transfer to an ex-spouse is a personal matter.

Industry Context

This insider transaction report is specific to the individual director's equity holdings and does not provide broader insights into industry trends or competitive landscape.

Related Party Transactions

• The sales were conducted by Arsenal Bridge Venture II, LLC and Arsenal Bridge Venture II-B, LLC, entities over which Director Isaac Barchas holds voting and investment power, making them related parties to the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, could be perceived by some as a slight reduction in insider alignment, though the 10b5-1 plan mitigates this interpretation.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction report.

Key Dates

Recommendation

The reported transactions are routine, pre-scheduled sales under a Rule 10b5-1 plan, which do not typically signal a change in the director's fundamental view of the company's prospects. The transfer of shares to an ex-spouse is a personal event. Therefore, this filing alone does not provide a basis for a change in investment recommendation; a 'hold' stance is maintained pending further operational or financial updates.

Keywords

Immunome Inc., IMNM, Insider Sale, Form 4, Isaac Barchas, 10b5-1 Plan, Director Transaction, Equity Sale, Common Stock